BioSpace News Archive

Bausch + Lomb Corporation, (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”, “we” or “our”), a leading global eye health company dedicated to helping people see better to live better, today announced its first-quarter 2023 financial results.

DexCom, Inc. (Nasdaq: DXCM) (“Dexcom”) announced today the pricing of its offering of $1.1 billion aggregate principal amount of 0.375% Convertible Senior Notes due 2028 (the “notes”) in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).

Kura Oncology, Inc. today announced that it will report first quarter 2023 financial results after the close of U.S. financial markets on Wednesday, May 10, 2023.

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced financial results for the first quarter ended March 31, 2023 and provided a business update.

Incannex Healthcare Ltd is pleased to announce a company presentation containing data and analysis of the results from the Phase 1 clinical trial undertaken to assess safety and pharmacokinetics of IHL-675A as an anti-inflammatory drug candidate.

Horizon Therapeutics plc (Nasdaq: HZNP) today announced first-quarter 2023 financial results.

Soligenix, Inc. announced today the appointment of Timothy R. Coté, M.D., M.P.H. to its Board of Directors.

Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS ® (Voclosporin) For Adults with Active Lupus Nephritis.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2023 and provided an update on its 2023 financial guidance.

Mersana Therapeutics, Inc. today announced that members of management will present at the Bank of America Securities 2023 Healthcare Conference on Wednesday, May 10, 2023 at 12:20 p.m. Eastern Time.